Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade
Do A, Mittal Y, Liapakis A, Cohen E, Chau H, Bertuccio C, Sapir D, Wright J, Eggers C, Drozd K, Ciarleglio M, Deng Y, Lim JK. Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade. PLOS ONE 2015, 10: e0135645. PMID: 26312999, PMCID: PMC4552165, DOI: 10.1371/journal.pone.0135645.Peer-Reviewed Original ResearchConceptsSofosbuvir/ledipasvirViral loadMedicaid coverageChild-Pugh class B diseaseInitial approvalEnd-stage liver disease (MELD) scoreStage liver disease scoreChronic HCV infectionClass B diseaseDrug authorizationHCV care cascadeSOF/LEDAdvanced liver diseaseBaseline viral loadHepatitis C infectionLiver Disease scoreRetrospective chart reviewHigh viral loadSignificant predictorsHigher likelihoodMedicare/MedicaidSOF/C infectionCare cascadeHCV infection